Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/13/2025

Antibiotic Allergy Management

Introduction to Metronidazole and Cefaclor

  • The Dutch Working Party on Antibiotic Policy (SWAB) guidelines (2023) state that metronidazole can be safely administered to patients with a cefaclor allergy as there is no cross-reactivity between these two classes of antibiotics, due to their structurally and mechanistically distinct properties 1
  • Metronidazole belongs to the nitroimidazole class, which is distinct from cephalosporins like cefaclor, and has activity against anaerobic bacteria and certain protozoans, with no cross-allergenicity existing between these distinct antibiotic classes 1

Treatment of Patients with Cefaclor Allergy

  • When treating a patient with a cefaclor allergy who needs anaerobic coverage, the American College of Clinical Pharmacy recommends assessing the nature of the cefaclor allergy, including whether it was immediate (IgE-mediated) or delayed-type, and noting the severity and timing of the previous reaction, before proceeding with metronidazole therapy as indicated 1
  • The Infectious Diseases Society of America suggests that metronidazole can be used as a reliable option for anaerobic coverage even in patients with multiple antibiotic allergies, with standard dosing (e.g., 500 mg three times daily for most infections) and no special precautions needed due to the cefaclor allergy 1
  • For alternative coverage for aerobic pathogens, the European Society of Clinical Microbiology and Infectious Diseases recommends considering fluoroquinolones (with metronidazole for anaerobic coverage) or carbapenems for broader coverage in severe infections 2

Important Considerations

  • The American Academy of Allergy, Asthma, and Immunology advises against confusing beta-lactam cross-reactivity with non-beta-lactam antibiotics, as metronidazole has no structural similarity to cephalosporins or penicillins, and against withholding necessary anaerobic coverage, as inadequate anaerobic coverage in mixed infections can lead to treatment failure and increased morbidity 1
  • The Society for Healthcare Epidemiology of America recommends not overlooking the need for aerobic coverage, as metronidazole alone is insufficient for mixed infections, and appropriate companion antibiotics are needed 2